Form 4: Erasca CMO Granted 625,000 Stock Options

Erasca, Inc.'s Chief Medical Officer, Shannon Morris, was granted 625,000 stock options with an exercise price of $10.31, vesting over four years.

Summary

• Shannon Morris, Chief Medical Officer of Erasca, Inc. (ERAS), was granted 625,000 stock options.
• The options have an exercise price of $10.31 per share.
• The grant date for these options was January 29, 2026.
• The options will vest monthly over a four-year period, with 1/48th of the shares vesting on the 29th day of each month (or the last day of February), beginning in February 2026.
• Vesting is contingent upon Ms. Morris's continuous service to the issuer.
• The options expire on January 29, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signals management retention and aligns executive incentives with long-term shareholder value, a standard practice in the biotech industry.

Positives

• The grant of stock options serves as an incentive for the Chief Medical Officer to remain with the company and contribute to its long-term success.
• Aligns management's interests with those of shareholders by tying compensation to future stock performance.

Negatives

• Potential future dilution for existing shareholders if the options are exercised, although this is a standard component of executive compensation.

Future Outlook

The vesting schedule indicates a long-term incentive structure for the Chief Medical Officer, aligning her future compensation with the company's performance over the next four years.

Industry Context

StockSavvy.ai notes that equity grants, particularly stock options with multi-year vesting schedules, are a common practice in the biotechnology and pharmaceutical sectors to attract, retain, and incentivize key scientific and executive talent. This grant to Erasca's CMO is consistent with industry standards for executive compensation, aiming to align leadership's long-term interests with shareholder value creation.

Comparison to Industry Standards

• The grant of 625,000 stock options to a Chief Medical Officer is a substantial equity award, typical for a company in the biotechnology sector, especially one focused on drug development where executive retention is critical.
• The four-year monthly vesting schedule is a standard industry practice, comparable to grants seen at companies like Moderna (MRNA) or BioNTech (BNTX) for their senior executives, designed to ensure long-term commitment and performance.
• The exercise price of $10.31, likely the market price on the grant date, is standard for at-the-money options, providing upside potential tied directly to future stock appreciation.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefits from incentivized management focused on long-term growth.
• Employees: Signals stability in key leadership and a commitment to executive retention.
• Management: Provides significant long-term incentive compensation tied to company performance.

Next Steps

• Monthly vesting of 1/48th of the shares subject to the option, starting February 2026.
• Continued service of Shannon Morris to Erasca, Inc. to ensure vesting.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation grant and does not provide sufficient information to alter a fundamental investment thesis. While the grant aligns management incentives, it's a standard practice and not a catalyst for a "buy" or "sell" recommendation based solely on this filing. Investors should hold and monitor broader company performance and strategic developments.

Keywords

Erasca, ERAS, Shannon Morris, Chief Medical Officer, CMO, stock options, equity grant, executive compensation, SEC Form 4, insider transaction